The decline of measles antibody titers in previously vaccinated adults: a cross-sectional analysis

ABSTRACT The global reemergence of measles in 2018-2019 reinforces the relevance of high-coverage immunization to maintain the disease elimination. During an outbreak in the Sao Paulo State in 2019, several measles cases were reported in individuals who were adequately vaccinated according to the current immunization schedule recommends. This study aimed to assess measles IgG antibody seropositivity and titers in previously vaccinated adults. A cross-sectional study was conducted at CRIE-HC-FMUSP (Sao Paulo, Brazil) in 2019. It included healthy adults who had received two or more Measles-Mumps-Rubella vaccines (MMR) and excluded individuals with immunocompromising conditions. Measles IgG antibodies were measured and compared by ELISA (Euroimmun®) and chemiluminescence (LIASON®). The association of seropositivity and titers with variables of interest (age, sex, profession, previous measles, number of measles-containing vaccine doses, interval between MMR doses, and time elapsed since the last MMR dose) was analyzed. A total of 162 participants were evaluated, predominantly young (median age 30 years), women (69.8%) and healthcare professionals (61.7%). The median interval between MMR doses was 13.2 years, and the median time since the last dose was 10.4 years. The seropositivity rate was 32.7% by ELISA and 75.3% by CLIA, and a strong positive correlation was found between the tests. Multivariate analyses revealed that age and time since the last dose were independently associated with positivity. Despite being a single-center evaluation, our results suggest that measles seropositivity may be lower than expected in adequately immunized adults. Seropositivity was higher among older individuals and those with a shorter time since the last MMR vaccine dose.

Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation

ABSTRACT The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.

Does BCG Or MMR Or Routine Vaccination Coverage Protect Against COVID Infection And Mortality In India?

Background: The routine vaccinations and acquired immunity by other viral infections were believed to be acting as a protective factor against severe COVID-19 outbreaks in some countries. Objective: This study is overviewing the relationship of routine BCG, MMR vaccinations and reported MMR disease outbreak with reported COVID-19 infection across the Indian states. Methods: The data on vaccination coverage and respiratory disease infection was obtained from Univer-sal immunization program and Integrated disease surveillance project reports. Spearman rank correla-tion has been used to assess the relationship of routine vaccination and COVID-19 infection. Results: The result did not find any relationship of routine vaccination with BCG and MMR or exposure to MMR infection on COVID-19 infections in India. Conclusion: The exposure to BCG or MMR vaccination did not have a non-specific protection against COVID-19 infection. The results imply that a larger proportion of the Indian population is still vulnerable to COVID-19 infection.

Situação vacinatória da tríplice e da tetra viral em crianças matriculadas na Educação Infantil / The vaccination situation of triple and tetra viral in children enrolled in Early Childhood Education

Objetivo Descrever a situação vacinal de crianças matriculadas nos Centros Municipais de Educação Infantil da Zona Sul do município de Natal, Rio Grande do Norte com relação às vacinas de tríplice e tetra viral. Método Trata-se de um estudo epidemiológico, descritivo e retrospectivo, realizado a partir da análise de cartões de vacina de crianças matriculadas em 15 instituições, nas quais foi possível reunir 773 cartões que foram analisados a partir do calendário básico de vacinação do ano 2015. Os cartões foram classificados em: esquema vacinal completo, incompleto e/ou não vacinado. Resultados Observou-se que 576 (75,51%) crianças estavam com o esquema vacinal completo, sendo o esquema considerado finalizado com a segunda dose da tríplice ou com a tetra viral. A melhor situação vacinal foi atingida nas crianças de dois a quatro anos, com uma cobertura de 84,31%, sendo que 83,3% das crianças dessa faixa etária estavam com o esquema completo e 12,79% das crianças estavam com o esquema vacinal incompleto. Um total de 67 crianças (8,66%) não apresentaram registros de vacina. Com relação à tetra viral, 226 crianças (29,73%) apresentaram esquema vacinal completo. Conclusão Os resultados obtidos no presente estudo revelam uma situação vacinal abaixo da meta estabelecida pelo Programa Nacional de Imunização.

Objective To describe a vaccination situation of children up to 8 years old from the Municipal Centers of Early Childhood Education in the South Zone of the city of Natal, Rio Grande do Norte for vaccines of triple and tetra viral. Method This is an epidemiological, descriptive and retrospective study, carried out based on the analysis of vaccination cards for children from 15 institutions, where it was possible to gather 773 cards, a course based on the basic calendar of the year 2015. They were classified in: complete, incomplete and/or unvaccinated vaccination schedule. Results It is observed that 576 (75.51%) of the children have a complete vaccination schedule, the schedule being completed with a second dose of triple or tetra viral. The best vaccination status was achieved in children aged 2 to 4 years with a coverage of 84.31% and 83.3% children with the complete regimen. We have 12.79% of children with an incomplete vaccination schedule. A total of 67 children (8.66%) who did not have any vaccine records. Regarding Tetra Viral, 226 children (29.73%) had a complete vaccination schedule. Conclusion The results obtained in this study reveal a vaccination situation below the target established by the National Immunization Program.

Evaluación neuroepidemiológica a partir de anticuerpos antivirales de memoria generados por la vacuna triple viral / Neuro-Epidemiological Evaluation From Memory Antiviral Antibodies Generated By The MMR Vaccine

Introducción: La vacuna contra sarampión-parotiditis-rubéola es administrada en Cuba con un 99 por ciento de cobertura vacunal. Actualmente se plantea la baja inmunogenicidad de la cepa de parotiditis con que se fabrica por lo que resulta importante velar por la eficacia de las vacunas y su respuesta inmune protectora. Objetivos: Evaluar el comportamiento de los índices de anticuerpo antirubéola, antiparotiditis y antisarampión de acuerdo con la edad, y analizar la variación de la respuesta de anticuerpos antiparotiditis con respecto a estudios anteriores. Materiales y métodos: Se estudiaron muestras de suero y líquido cefalorraquídeo de 42 pacientes pediátricos con procesos neuroinflamatorios y se les cuantificó IgG total y albúmina y anticuerpos específicos contra los tres virus a partir de ensayos innmunoenzimáticos tipo ELISA. Se realizaron los reibergramas correspondientes e índices de anticuerpos específicos. Resultados: Se observó un incremento sostenido de anticuerpos contra los tres inmunógenos de forma general, sin diferencias significativas por razones de edad ni cambios notables posrevacunación. Existió un decrecimiento del índice de anticuerpos a medida que se alejaba de la fecha de revacunación por lo que se debe mantener una vigilancia en esos grupos de edades. La velocidad de producción de anticuerpos antiparotiditis fue mayor que frente a los otros virus, aunque no de forma significativa. Conclusiones: Esta vacuna garantiza protección por la uniformidad de la respuesta inmune de memoria inducida en todos los grupos de edades. Se demostró un aumento de protección de la población estudiada frente a la parotiditis con respecto a estudios previos(AU)

Introduction: The measles-mumps-rubella vaccine is administered in Cuba with 99 percent vaccination coverage. Currently, the low immunogenicity of the strain of mumps with which it is manufactured is raised, so it is important to ensure the effectiveness of vaccines and their protective immune response. Objectives: Evaluate the behavior of the anti-rubella, anti-mumps and anti-measles antibody indices according to age, and to analyze the variation of the anti-mumps antibody response with respect to previous studies. Materials and methods: Serum and cerebro-spinal fluid samples from 42 pediatric patients with neuro-inflammatory processes were studied and total IgG and albumin and specific antibodies against the three viruses were quantified from immunoenzymatic assays ELISA type. Corresponding reibergrams and specific antibody indices were performed. Results: A sustained increase in antibodies against the ethree immunogens was observed in general, without significant differences due to age or notable post-vaccination changes. There was a decrease in the antibody index as it moved away from the date of revaccination, so surveillance should be maintained in these age groups. The rate of production of anti-mumps antibodies was higher than against the other viruses, although not significantly. Conclusions: This vaccine guarantees protection by the uniformity of the memory induced immune response in all age groups. An increase in the protection of the studied population against mumps was demonstrated with respect to previous studies(AU)

Identificación de desórdenes autoinmunes e inmunodeficiencias a través de la evaluación neuroepidemiológica del índice de anticuerpos antiparotiditis, antirubéola y antisarampión / Identification of autoimmune disorders and immunodeficiencies by neuroepidemiological evaluation of the measles, mumps and rubella antibody index

Introducción: El esquema nacional de vacunación cubano presenta coberturas superiores al 99 por ciento que incluye la vacuna contra parotiditis, rubéola y sarampión. Así, cuando existe un proceso neuroinflamatorio se produce una amplia síntesis intratecal de anticuerpos antiparotiditis, antirubéola y antisarampión, que permite realizar evaluaciones neuroepidemiológicas de las campañas de vacunación y el sesgo de casos extremos, desde el punto de vista inmunológico. Objetivos: Correlacionar el índice de anticuerpos antirubéola, antiparotiditis y antisarampión con procesos autoinmunes asociados y en la identificación de posibles pacientes con inmunodeficiencias en la muestra estudiada. Métodos: Se realizó un estudio aplicado y descriptivo de corte transversal en 42 niños evaluados en los servicios de cuerpo de guardia de los hospitales pediátricos de La Habana del 2015 al 2018. La muestra fue dividida según los tres intervalos del índice de anticuerpos (menor o igual a 0,6; de 0,6 a 1,5 y mayor o igual a 1,5). Se procedió a detectar en los segmentos extremos pacientes con posible autoinmunidad (mayor o igual a 1,5) e inmunodeficiencia (se tomó el intervalo inferior a una desviación estándar). Resultados: En el grupo con índice de anticuerpos mayor o igual a 1,5, el 75 por ciento fue positivo a la reacción MRZ, indicativo de una enfermedad autoinmune activa. En el grupo con índice de anticuerpos menor o igual a 0,6 preponderó una clínica con prevalencia de enfermedades tumorales e infecciosas asociadas a un alto índice de hospitalización, test de inmunodeficiencia positivo y bajos niveles de IgG en suero. Conclusiones: Es posible identificar pacientes pediátricos con desórdenes autoinmunes y sospecha de inmunodeficiencias, a partir de la estrategia de la evaluación neuroepidemiológica de los índices de anticuerpos antiparotiditis, antirubéola y antisarampión(AU)

Introduction: The Cuban national vaccination scheme has a coverage of more than 99 percent of the population, and includes the measles-mumps-rubella vaccine. Therefore, in the presence of a neuroinflammatory process, a broad intrathecal synthesis of measles, mumps and rubella antibodies takes place which makes it possible to conduct neuroepidemiological evaluations of the vaccination campaigns and the bias of extreme cases, from an immunological perspective. Objectives: Correlate the measles, mumps and rubella antibody index with associated autoimmune processes and in the identification of patients with possible immunodeficiencies in the study sample. Methods: An applied cross-sectional descriptive study was conducted of 42 children attending the emergency services of Havana children's hospitals in the period 2015-2018. The sample was divided according to the three antibody index intervals: smaller than or equal to 0.6, from 0.6 to 1.5, and greater than or equal to 1.5. Extreme segments were examined to detect patients with possible autoimmunity (greater than or equal to 1.5) and immunodeficiency (the interval below a standard deviation was taken as reference). Results: 75 percent of the group with an antibody index greater than or equal to 1.5 was positive to the MRZ reaction, indicative of an active autoimmune disease. In the group with an antibody index lower than or equal to 0.6, the prevailing clinical status showed a prevalence of tumoral and infectious diseases associated to a high hospitalization index, a positive immunodeficiency test and low serum IgG levels. Conclusions: It is possible to identify pediatric patients with autoimmune disorders and suspicion of immunodeficiencies applying the strategy of neuroepidemiological evaluation of the measles, mumps and rubella antibody indices(AU)

Estrutura e localização dos serviços de vacinação influenciam a disponibilidade da tríplice viral no Brasil / La estructura y ubicación de los servicios de vacunación influyen en la disponibilidad de la vacuna triple viral en Brasil / Structure and location of vaccination services influence the availability of the triple viral in Brazil

RESUMO OBJETIVO: analisar a associação de fatores estruturais e diferenças geográficas na disponibilidade da vacina tríplice viral nos serviços de atenção básica no Brasil. MÉTODOS: estudo transversal, com dados secundários do segundo ciclo das avaliações externas do Programa de Melhoria da Qualidade da Atenção Básica (PMAQ-AB) coletados em 19.752 serviços de vacinação de todo o país entre os anos de 2013 e 2014. Razões de prevalência (RP) ajustadas e seus respectivos intervalos de confiança de 95% (IC 95%) foram estimados com a técnica de regressão multivariada de Poisson com variâncias robustas. RESULTADOS: a vacina tríplice viral estava sempre disponível em 93% dos serviços estudados, mas com diferenças regionais, sendo a menor frequência observada na região Norte (87,4%; p<0,001). Os seguintes fatores estruturais dos serviços associaramse positivamente à maior frequência de vacina tríplice viral sempre disponível: possuir sala de vacinação (RP: 1,05; IC 95%: 1,01-1,09), sala de vacinação exclusiva para imunização (RP: 1,04; IC 95% 1,02-1,05), geladeira exclusiva para vacinas (RP: 1,13; IC 95%: 1,10-1,16); cartões de vacinação impressos sempre disponíveis (RP: 1,12 IC 95%: 1,09-1,16) e caixas térmicas para vacinas sempre disponíveis (RP: 1,18 IC 95%: 1,14-1,21). CONCLUSÃO: a localização e a estrutura dos serviços de atenção básica influenciaram na disponibilidade da vacina tríplice viral no Brasil. Serviços da região Norte e com estrutura deficiente para as ações de imunização apresentaram menor frequência da disponibilidade da vacina.

RESUMEN OBJETIVO: analizar la asociación entre los factores estructurales y las diferencias geográficas en la disponibilidad de la vacuna triple viral en los servicios de atención primaria de Brasil. MÉTODO: estudio transversal con datos secundarios del segundo ciclo de evaluaciones externas del Programa de mejora de la calidad de la atención primaria recogidos en 19.752 servicios de vacunación de todo el país entre 2013 y 2014.Las razones de prevalencia ajustadas (PR) y sus respectivos intervalos de confianza del 95% (IC del 95%) se estimaron utilizando la técnica de regresión multivariante de Poisson con varianzas robustas. RESULTADOS: la vacuna triple viral siempre estuvo disponible en el 93% de los servicios estudiados, pero con diferencias regionales, con la menor frecuencia observada en el norte (87,4%; p <0,001). Los siguientes factores estructurales de los servicios se asociaron positivamente con la mayor frecuencia de vacuna triple viral siempre disponible: tener una sala de vacunación (RP: 1.05; IC 95%: 1.01-1.09), sala de vacunación exclusiva para inmunización (RP: 1,04; IC del 95%: 1,02-1,05), refrigerador exclusivamente para vacunas (RP: 1,13; IC del 95%: 1,10-1,16); tarjetas de vacunación impresas siempre disponibles (RP: 1,12 IC 95%: 1,09-1,16) y cajas térmicas para vacunas siempre disponibles (RP: 1,18 IC 95%: 1,14-1,21). CONCLUSIÓN: la ubicación y estructura de los servicios de atención primaria influyó en la disponibilidad de la vacuna triple viral en Brasil. Los servicios de la región norte con estructura deficiente para las acciones de inmunización mostraron menor frecuencia de disponibilidad de vacunas.

ABSTRACT OBJECTIVE: to analyze the association of structural factors and geographical differences in the availability of the measle, mumps, and rubella vaccine in primary care services in Brazil. METHODS: this is a cross-sectional study, with secondary data from the second cycle of external evaluations of the Primary Care Quality Improvement Program (Programa de Melhoria da Qualidade da Atenção Básica - PMAQ-AB) collected from 19,752 vaccination services across the country between 2013 and 2014. We estimated the prevalence ratio (PR) and their respective 95% confidence intervals (CI 95%) using the Poisson multivariate regression technique with robust variances. RESULTS: the MMR vaccine was always available in 93% of the services studied, but with regional differences, with the lowest frequency observed in the North (87.4%; p <0.001). The following structural factors of the services were positively associated with the higher frequency of MMR vaccine always available: having a vaccination room (PR: 1.05; 95% CI: 1.01-1.09), exclusive vaccination room for immunization (PR: 1.04; 95% CI 1.02-1.05), refrigerator exclusively for vaccines (PR: 1.13; 95% CI: 1.10-1.16); printed vaccination cards always available (PR: 1.12 95% CI: 1.09-1.16) and coolers for vaccines always available (PR: 1.18 95% CI: 1.14-1.21). CONCLUSION: the location and structure of primary care services influenced the availability of the MMR vaccine in Brazil. Services in the North region and with a poor structure for immunization actions showed less frequency of vaccine availability.

Seroprevalence of mumps in healthcare workers in South Korea

@#<![CDATA[Mumps is contagious disease and maintaining immunity to mumps in healthcare worker (HCW) is important for preventing transmission in the hospital. We evaluated the seroprevalence of mumps in HCWs in a tertiary care hospital in Republic of Korea. A total of 6,055 HCWs born between 1950 and 1995 underwent antibody testing. The overall seropositivity rate of mumps was 87% (95% confidence interval, 86%–87%). Our data indicates that, in Korean HCWs, testing for mumps antibody followed by mumps vaccination is more appropriate than routine mumps vaccination without testing for mumps antibody.]]>

Frecuencia de las reacciones alérgicas a la vacuna triple viral en pacientes con alergia al huevo / The frequency of allergic reactions to the triple viral vaccine in 94 patients with egg allergy

Introducción. La vacunación es la intervención en salud pública más efectiva de todos los tiempos, pues reduce la mortalidad y la morbilidad de múltiples enfermedades infecciosas. En muchas ocasiones, la aplicación de las vacunas se retrasa por el temor a las reacciones alérgicas, lo cual es frecuente entre los pacientes con alergia al huevo que requieren la vacuna triple viral (rubeola-sarampión-parotiditis). Objetivo. Evaluar la frecuencia de reacciones después de la aplicación de la vacuna triple viral en una población alérgica al huevo. Materiales y métodos. Se hizo un estudio retrospectivo multicéntrico (2014-2016) de pacientes con alergia al huevo que acudieron a centros de alergología de Medellín y requerían la aplicación de la vacuna triple viral. Resultados. Noventa y cuatro pacientes cumplían los criterios de selección; 68,2 % de ellos presentaba síntomas cutáneos al consumir huevo; 22,3 %, reacción anafiláctica; 5,3 %, síntomas gastrointestinales, y 4,2 %, síntomas respiratorios. Independientemente de la gravedad de su reacción al huevo, todos los pacientes recibieron la vacuna triple viral y la toleraron bien. Conclusión. Aunque la alergia al huevo es frecuente en la edad infantil, el riesgo de reacciones alérgicas después de aplicar la vacuna triple viral en esta población fue similar al de la población general, por lo que no se debe diferir su aplicación, incluso en pacientes con antecedentes de reacciones graves al huevo.

Introduction: Vaccination is the most effective public health intervention of all times, reducing the death and morbidity rates derived from multiple infectious diseases. In many cases, the administration and reception of vaccines is delayed due to the fear of allergic reactions; this is frequent among patients with allergy to egg who need the triple viral vaccine. Objective: To evaluate the frequency of reactions after the administration of triple viral vaccine (Measles, Mumps and Rubella, MMR) in an egg-allergic population. Materials and methods: We conducted a multi-center retrospective study (2014-2016) including patients with egg allergy who visited an allergology center and required the administration of the triple viral vaccine. Results: A total of 94 patients met the selection criteria. From these patients, 68.2% had cutaneous symptoms, 22.3% had an anaphylactic reaction, 5.3% had gastrointestinal symptoms, and 4.2% had respiratory egg-related symptoms. Regardless of the severity of their reaction to egg, all patients received the triple viral vaccine and in 100% of the cases, it was well tolerated. Conclusion: Although egg allergy is common in childhood, the risk of allergic reactions during the MMR vaccination in this population was similar to that in the general population, therefore, its use should not be deferred even in patients with a history of severe egg-related allergic reactions.

Incidence of varicella in children in Jeju-do, Korea, 2005–2016: age-period-cohort analysis / 한국역학회지

OBJECTIVES: Although the nationwide inoculation rate of varicella vaccine was approximately 95% in Korean children recently, the number of notified varicella cases is unexpectedly continuously increasing till now. To suggest some hypotheses regarding this discrepancy, an age-period-cohort (APC) analysis as a descriptive epidemiology study was conducted for children residing in Jeju-do, Korea. METHODS: The raw data were obtained from the nationwide database for insurance claim of healthcare fee provided by the National Health Insurance Service, Korea. The selection criteria were children aged 2–13 years who visited any healthcare center due to varicella from 2005 to 2016 while residing in Jeju-do. After calculating the birth cohort-specific crude incidence rates by age and year, the intrinsic estimator method was used to perform the APC analysis. RESULTS: As the annual crude incidence rates decreased with increasing age between 2005 and 2016, the age and period effects also decreased. The intrinsic estimator coefficients suggesting the cohort effect shifted from positive to negative in 2011, the starting year of free varicella vaccine program in Jeju-do. CONCLUSIONS: The results suggested that inoculated varicella vaccines have preventive effects. However, further studies to evaluate waning immunity would be needed.

Incidence of varicella in children in Jeju-do, Korea, 2005–2016: age-period-cohort analysis / 한국역학회지

OBJECTIVES: Although the nationwide inoculation rate of varicella vaccine was approximately 95% in Korean children recently, the number of notified varicella cases is unexpectedly continuously increasing till now. To suggest some hypotheses regarding this discrepancy, an age-period-cohort (APC) analysis as a descriptive epidemiology study was conducted for children residing in Jeju-do, Korea.METHODS: The raw data were obtained from the nationwide database for insurance claim of healthcare fee provided by the National Health Insurance Service, Korea. The selection criteria were children aged 2–13 years who visited any healthcare center due to varicella from 2005 to 2016 while residing in Jeju-do. After calculating the birth cohort-specific crude incidence rates by age and year, the intrinsic estimator method was used to perform the APC analysis.RESULTS: As the annual crude incidence rates decreased with increasing age between 2005 and 2016, the age and period effects also decreased. The intrinsic estimator coefficients suggesting the cohort effect shifted from positive to negative in 2011, the starting year of free varicella vaccine program in Jeju-do.CONCLUSIONS: The results suggested that inoculated varicella vaccines have preventive effects. However, further studies to evaluate waning immunity would be needed.

Anafilaxia relacionada à vacina sarampo, caxumba e rubéola, Santa Catarina, Brasil, 2014 e 2015 / Anaphylaxis related to measles, mumps, and rubella vaccine in Santa Catarina State, Brazil, 2014 and 2015 / Anafilaxia relacionada a la vacuna sarampión, paperas y rubeola, Santa Catarina, Brasil, 2014 y 2015

Resumo: Os objetivos consistiram em descrever os casos e verificar a frequência de anafilaxia relacionada à vacina sarampo, caxumba e rubéola (SCR) do produtor A, bem como avaliar os possíveis fatores de risco associados. Estudo de caso-controle (1:4), em Santa Catarina, Brasil, de 14 de julho de 2014 a 12 de janeiro de 2015, em crianças de um a menores de cinco anos, vacinadas com SCR e notificadas com anafilaxia, sendo os controles sem anafilaxia. Utilizou-se, como medida de associação, odds ratio (OR) com intervalo de 95% de confiança (IC95%) e os testes qui-quadrado e exato de Fisher. Calcularam-se taxas de anafilaxia por doses distribuídas/aplicadas. Entrevistaram-se 15 casos e 60 controles, em 12 municípios. As taxas de anafilaxia foram 2,46 e 5,05 por doses distribuídas e aplicadas, respectivamente. Dentre os casos de anafilaxia, oito (53,4%) eram do sexo masculino, e dentre os controles, 36 (60%), com p = 0,64. Na análise bivariada referente à anafilaxia e alergia à proteína do leite de vaca (APLV), verificou-se OR = 51,62, com p = 0,00002 e IC95%: 5,59-476,11. As variáveis alergia alimentar familiar, aleitamento materno, evento adverso pós-vacinação (EAPV) anterior e vacinação simultânea não foram estatisticamente significativas (p = 0,48; p = 1,00; p = 0,49; p = 0,61). Taxas de anafilaxia por doses distribuídas/aplicadas ficaram acima de 1/100 mil doses aplicadas (taxa esperada). Anafilaxia e APLV apresentaram associação estatisticamente significativa. Não foram encontradas associações estatísticas referentes à vacinação simultânea, aleitamento materno, alergia alimentar familiar e EAPV anterior. Recomendou-se ao produtor informar na bula todos os componentes do produto e que crianças com história pregressa de APLV não sejam vacinadas com essa vacina.

Abstract: The study aimed to describe cases and verify the frequency of anaphylaxis related to measles, mumps, and rubella (MMR) vaccine produced by manufacturer A and to assess associated risk factors. This was a case-control study (1:4) in Santa Catarina State, Brazil, from July 14, 2014, to January 12, 2015, in children from one year to less than five years of age, vaccinated with MMR and reported with anaphylaxis, while the controls were without anaphylaxis. The measure of association was odds ratio (OR) with 95% confidence interval (95%CI), using the chi-square and Fisher's exact tests. Anaphylaxis rates were calculated per doses distributed/administered. Fifteen cases and 60 controls were interviewed in 12 municipalities (counties). Anaphylaxis rates were 2.46 and 5.05 cases per 100,000 doses distributed and administered, respectively. Among the cases of anaphylaxis, eight (53.4%) were males, and among the controls, 36 (60%), with p = 0.64. The bivariate analysis of anaphylaxis and cow's milk protein allergy (CMPA) showed OR = 51.62, with p = 0.00002 and 95%CI: 5.59-476.11. The variables family food allergy, breastfeeding, previous post-vaccine adverse event (PVAE), and simultaneous vaccination were not statistically significant (p = 0.48; p = 1.00; p = 0.49; p = 0.61). Anaphylaxis rates per doses distributed/administered exceeded 1/100,000 doses administered (expected rate). Anaphylaxis and CMPA showed a statistically significant association. No statistically significant associations were found with simultaneous vaccination, breastfeeding, family food allergy, or history of PVAE. Recommendations: the manufacturer should specify the product's components in the package insert, and children with a history of CMPA should not be vaccinated with this vaccine.

Resumen: Los objetivos consistieron en describir los casos y verificar la frecuencia de anafilaxia, relacionada con la vacuna del sarampión, paperas y rubeola (SCR) del productor A, así como evaluar los posibles factores de riesgo asociados. Estudio de caso-control (1:4), en Santa Catarina, Brasil, de 14 de julio de 2014 a 12 de enero de 2015, en niños de uno a menores de cinco años, vacunadas con SCR y notificadas con anafilaxia, siendo los controles sin anafilaxia. Se utilizó, como medida de asociación, odds ratio (OR) con un intervalo de 95% de confianza (IC95%) y los testes chi-cuadrado y exacto de Fisher. Se calcularon las tasas de anafilaxia por dosis distribuidas/aplicadas. Se entrevistaron 15 casos y 60 controles, en 12 municipios. Las tasas de anafilaxia fueron 2,46 y 5,05 por dosis distribuidas y aplicadas, respectivamente. Entre los casos de anafilaxia, ocho (53,4%) eran del sexo masculino, y entre los controles, 36 (60%), con p = 0,64. En el análisis bivariado referente a la anafilaxia y alergia a la proteína de leche de vaca (APLV), se verificó OR = 51,62, con p = 0,00002 e IC95%: 5,59-476,11. Las variables alergia alimentaria familiar, lactancia materna , evento adverso pos-vacunación (EAPV) anterior y vacunación simultánea no fueron estadísticamente significativas (p = 0,48; p = 1,00; p = 0,49; p = 0,61). Tasas de anafilaxia por dosis distribuidas/aplicadas se situaron encima de 1/100.000 dosis aplicadas (tasa esperada). Anafilaxia y APLV presentaron una asociación estadísticamente significativa. No fueron encontradas asociaciones estadísticas referentes a la vacunación simultánea, lactancia materna, alergia alimentaria familiar y EAPV anterior. Se recomendó al productor informar en el prospecto sobre todos los componentes del producto, y que los niños con historial anterior de APLV no sean vacunados con esa vacuna.

MMR2 vaccination coverage and timeliness among children born in 2004 - 2009: a national survey in Saint Lucia, 2015 / Cobertura de vacunación y respeto de los plazos de la segunda dosis de la vacuna triple viral en los niños nacidos en el período 2004-2009: encuesta nacional realizada en Santa Lucía en el 2015 / Cobertura e momento oportuno de vacinação da segunda dose da vacina tríplice viral em crianças nascidas em 2004-2009: pesquisa nacional em Santa Lúcia, 2015

ABSTRACT Objectives To more accurately determine coverage and timeliness of the second dose of measles-mumps-rubella vaccine (MMR2), while identifying factors associated with low MMR2 vaccination uptake among children in Saint Lucia. Methods A survey was conducted in October - November 2015 targeting children born in 2004 - 2009. At 86 preschools and primary schools, two children from each grade were randomly selected, yielding an effective sample of 836 children. Health records were reviewed to assess vaccination coverage and timeliness. Parents and/or guardians and principals of all 86 schools were interviewed regarding knowledge, attitudes, and practices related to vaccination. Results Of 767 children included, 75% were vaccinated with MMR2 (n = 572); 46.7% were vaccinated in a timely manner, i.e., by 5 years of age. Cohorts born in 2004, 2005, and 2008 reported the lowest proportion. 'Mothers as caregivers' was positively associated with timely MMR2 vaccination. Although 97% of principals surveyed considered vaccination important, 48.8% were not aware of national legislation requiring complete vaccination prior to school entry. Survey results concurred with the low MMR2 administrative coverage rates reported by Saint Lucia, much lower than the recommended 95%. Conclusions Based on the results of this survey, Saint Lucia's national immunization program has lowered the age of MMR2 to 18 months in 2016, increased advocacy with schools to enforce the school-entry law, and is working to vaccinate the cohorts of children who have not received timely MMR2.

RESUMEN Objetivos Determinar con mayor precisión la cobertura y el respeto de los plazos de vacunación de la segunda dosis de la vacuna contra el sarampión, la rubéola y la parotiditis (triple viral), al tiempo que se detectan los factores asociados con la baja aceptación de esa vacuna en Santa Lucía. Métodos En octubre y noviembre del 2015 se llevó a cabo una encuesta centrada en niños nacidos entre el 2004 y el 2009. En 86 centros preescolares y primarios se seleccionó al azar a dos niños de cada grado, lo que arrojó un tamaño real de la muestra de 836 niños. Se analizaron los registros de salud para evaluar la cobertura y el respeto de los plazos de vacunación. Se entrevistó a los padres o tutores y los directores de las 86 escuelas sobre conocimientos, actitudes y prácticas en materia de vacunación. Resultados De los 767 niños incluidos, el 75% fueron vacunados con la segunda dosis de la triple viral (n = 572); el 46,7% fueron vacunados a tiempo, es decir, a los 5 años de edad. La proporción más baja se dio en las cohortes nacidas en el 2004, 2005 y 2008. Se observó que las madres cuidadoras influían positivamente en el respeto de los plazos de vacunación de la segunda dosis de la triple viral. Aunque el 97% de los directores encuestados consideraba que la vacunación era importante, el 48,8% desconocía la legislación nacional que exige la vacunación completa antes de ingresar a la escuela. Los resultados de la encuesta estaban en consonancia con las tasas bajas de cobertura administrativa de la segunda dosis de la triple viral informadas por Santa Lucía, muy por debajo del 95% recomendado. Conclusiones Según los resultados de esta encuesta, el programa nacional de vacunación de Santa Lucía redujo la edad de la segunda dosis de la triple viral a los 18 meses en el 2016, aumentó las actividades de promoción en las escuelas para fomentar el cumplimiento de la ley que obliga a recibir la vacunación antes de ingresar a la escuela y está trabajando para vacunar a las cohortes de niños que no recibieron la segunda dosis de la triple viral en su debido momento.

RESUMO Objetivos Determinar com precisão a cobertura vacinal e o momento oportuno para ministrar a segunda dose da vacina tríplice viral (sarampo, caxumba e rubéola - SCR) e identificar os fatores associados à baixa utilização da vacina em crianças. Métodos Uma pesquisa direcionada a crianças nascidas de 2004 a 2009 foi realizada em Santa Lúcia em outubro e novembro de 2015. Em 86 unidades de ensino infantil e fundamental, duas crianças de cada série foram selecionadas aleatoriamente, constituindo uma amostra efetiva de 836 crianças. Dados sobre a cobertura e o momento oportuno de vacinação foram obtidos das fichas de saúde. Foram conduzidas entrevistas com os pais e/ou responsáveis e os diretores das 86 escolas sobre conhecimento, atitudes e práticas relacionadas à vacinação. Resultados Das 767 crianças incluídas na amostra, 75% foram vacinadas com a segunda dose de SCR (n = 572) e 46,7% receberam a vacina no momento oportuno (ou seja, até os 5 anos de idade). Observou-se menor proporção de vacinados nas coortes nascidas em 2004, 2005 e 2008. "Mães como cuidadoras" teve uma associação positiva com ministrar a segunda dose de SCR no momento oportuno. Apesar de 97% dos diretores entrevistados considerarem a vacinação importante, 48,8% desconheciam a legislação nacional que exige vacinação completa para a matrícula escolar. Os resultados reforçaram a baixa cobertura vacinal da segunda dose de SCR registrada em Santa Lúcia, bem inferior ao índice recomendado de 95%. Conclusões A partir dos resultados desta pesquisa, em 2016, o programa nacional de vacinação de Santa Lúcia reduziu para 18 meses a idade de administração da segunda dose de SCR, intensificou a recomendação para que as escolas cumpram com a legislação para matrícula escolar e está empenhado em vacinar as coortes de crianças que não receberam a segunda dose de SCR no momento oportuno.

Administración satisfactoria de la vacuna triple viral mediante una prueba de provocación gradual en una paciente con anafilaxia después de una vacunación previa / Successful administration of measles-rubella-mumps vaccine by graded challenge in a case with anaphylaxis after prior vaccination

La alergia al huevo es una de las alergias alimentarias más frecuentes durante la niñez, junto con la alergia a la leche de vaca. La vacuna triple viral (VTV), contra el sarampión, la rubéola y las paperas, es parte del calendario de vacunación pediátrica y contiene proteína de huevo. La recomendación aceptada en la actualidad es que la VTV debe administrarse en una sola dosis y bajo supervisión médica en los pacientes con alergia al huevo. Si bien se ha informado que la VTV es segura para estos pacientes, algunos tuvieron anafilaxia. En general, la anafilaxia después de una vacunación previa se considera una contraindicación. En este artículo, presentamos el caso de la administración satisfactoria de la VTV mediante el incremento gradual de la dosis a una paciente que tuvo anafilaxia después de una vacunación previa.

Egg allergy is one of the most common food allergies during childhood along with cow's milk allergy. The measles-mumps-rubella (MMR) vaccine is included in the pediatric immunization schedule and contains egg protein. The currently accepted opinion is that the MMR vaccination should be done in a single dose under medical observation in patients with egg allergy. Although it is reported that the MMR vaccine is safe for that patients, there are some patients who developed anaphylaxis. Generally, the development of anaphylaxis after the previous vaccination is reported as a contraindication. We present a successful administration of MMR vaccine by gradually increased doses for a patient who developed anaphylaxis after the previous vaccination.

Efficacy of a second dose measles-mumps-rubella vaccine in children in Xicheng District, Beijing, China in 2016 / 中华微生物学和免疫学杂志

Objective To analyze the efficacy of a second dose of measles-mumps-rubella (MMR) vaccine in children aged 6 to 7 years in Xicheng District, Beijing, China in 2016.Methods Serum samples were collected in duplicate from 41 children aged 6 to 7 years before and one month after immunization with a second dose of MMR vaccine.ELISA was performed to detect IgG antibodies against measles, rubella and mumps in serum samples.Results The positive rates of antibodies against measles, rubella and mumps in the 41 children before immunization with a second dose of MMR vaccine were 95.12%, 90.24% and 92.68% and the antibody titers were (825.88±499.91), (53.83±32.48) and (697.83±535.82) IU/ml, respectively.The positive rates of the three antibodies were 100%, 97.56% and 100% after revaccination with MMR vaccine and the antibody titers were (1 102.98±356.77), (95.08±26.88) and (3 383.85±1 903.06) IU/ml.Titers of antibodies against measles, rubella and mumps increased significantly following revaccination (P0.05).Conclusion The second dose immunization of MMR vaccine achieves a high successful rate in children in Xicheng District of Beijing.It would be an effective immunization strategy to protect children from measles, rubella and mumps.

Is it Right Time to Introduce Mumps Vaccine in India’s Universal Immunization Program.

Measles, mumps and rubella are vaccine preventable diseases. However, morbidity and mortality due to these diseases remain largely unnoticed in India. Measles has received much attention; mumps and rubella still need to garner attention. According to the World Health Organization, near-elimination of mumps could be achieved by maintaining high vaccine coverage using a two-dose strategy. However, Government of India has not yet decided on mumps vaccine. In this review, we have reviewed sero-prevalence studies, vaccine studies, outbreak investigations, virus isolation and virus genotyping studies on mumps. Overall, mumps seems to be a significant public health problem in India, but does not garner attention due to the absence of a surveillance and documentation system. Thus, inclusion of mumps antigen in the Universal immunization program would have added advantages, the economic burden imposed by the cost of the vaccine offset by a reduction in disease burden.

Factors associated with mumps meningitis and the possible impact of vaccination / 소아과

PURPOSE: Mumps meningitis is a common complication of mumps infection; however, information on mumps meningitis in the postvaccine era is limited. The purpose of the present study was to determine factors associated with mumps meningitis and to discuss the effect of vaccination on this disease. METHODS: We retrospectively reviewed patients younger than 19 years with mumps, diagnosed at a university hospital in Korea between 2003 and 2013. Patients were divided into groups with and without meningitis, and the clinical features of the 2 groups were compared. RESULTS: The study enrolled 119 patients: 19 patients with meningitis and 100 patients without. Univariate analysis showed that older age (median: 15 years vs. 9.5 years, respectively), a longer interval from last vaccination (median: 10.2 years vs. 4.8 years, respectively), and febrile presentation (94.7% vs. 31.0%, respectively) were significantly associated with mumps meningitis. Sex, number of vaccination doses, bilateral parotitis, and the presence of complications other than meningitis did not differ between the 2 groups. In multivariate logistic regression analysis, age (odds ratio, 1.38; 95% confidence interval, 1.01-1.89; P=0.04) and fever (odds ratio, 30.46; 95% confidence interval, 3.27-283.61; P<0.01) remained independent factors for mumps meningitis. CONCLUSION: Clinicians in the postvaccine era should be aware of the possibility of mumps meningitis in febrile cases of mumps in adolescents, regardless of the number of vaccination doses. To establish the role of vaccination in mumps meningitis, further studies will be necessary.

IAP Position Paper on Burden of Mumps in India and Vaccination Strategies.

Justification: Mumps, despite being a widely prevalent disease in the country, is considered as an insignificant public health problem mainly because of poor documentation of clinical cases and lack of published studies. In the absence of adequate published data on disease burden, Government of India has recently decided to introduce measles-rubella (MR) vaccine in its National Immunization Program and neglected mumps component. Process: Following an IAP ACVIP meeting on December 6 and 7, 2014, a detailed review of burden of mumps in India along with vaccination strategies to control the disease was prepared. The draft was circulated amongst the members of the committee for review and approval. Revised final draft was later approved by IAP executive board in January 2015. Objectives: To provide a review of community burden of mumps in India; and to discuss the vaccination strategies to impress upon policymakers to include mumps vaccination in National immunization program. Recommendations : A total of 14 studies and two media reports on mumps outbreak were retrieved. The outbreaks were reported from all the regions of the country. Mumps meningoencephalitis was responsible for 2.3% to 14.6% of all investigated hospitalized acute encephalitis syndrome or viral encephalitis cases in different studies. Data from Infectious Disease Surveillance (ID Surv) portal of IAP and Integrated Disease Surveillance Program (IDSP) of Government of India (GoI) were also reviewed. While a total of 1052 cases were reported by the IDSurv, IDSP had investigated 72 outbreaks with 1564 cases in 14 states during different time periods. Genotypes G (subtype G2) and C were found to be main genotypes of the mumps virus circulating in the country. Three studies studied serological status of young children and adolescents against mumps, and found susceptibility rates ranging from 32% to 80% in different age groups. Conclusions: Mumps poses a significant disease burden in India. This calls for inclusion of mumps vaccine in the National immunization program.

Commitment of Measles Elimination by 2020: Challenges in India.

The eleven member states of World Health Organization South-East Asia Region committed to eliminate measles by 2020. In phased manner, Government of India is working on this goal, and has introduced two-dose strategy for measles vaccine in the routine immunization. Molecular epidemiology of measles in India has been considerably growing that would be useful for understanding the circulation of wild type measles in pre- and post-elimination period. However, importations of cases from other countries may be likely. This article describes major challenges to achieve the measles elimination goal in India.

IAP Perspectives on Measles and Rubella Elimination Strategies.

The Academy’s Expert group on Immunization has discussed various issues pertaining to rubella vaccine introduction in to the Universal Immunization Program. Though the move to introduce rubella vaccine in to the UIP is laudable, the decision to overlook mumps seems inexplicable and illogical. Logistics also support the use of measles-mump and rubella (MMR) vaccine instead of measles-rubella (MR) vaccine. Regarding the timing of administration of MMR/MR vaccine, the academy recommends that the vaccine should be given early to have much higher coverage than introducing it late at the time of 1st booster of DPT. According to available evidence, both these vaccines (MMR/MR) can be given safely at different ages including at 9 months of age. The second dose should also be of the same antigen (MMR/ MR) and be given along with 1st DPT booster at 16-24 months of age.